Home › Funds › Affinity Asset Advisors, LLC › SYRE
Affinity Asset Advisors, LLC position in SYRE
SPYRE THERAPEUTICS INC · Health Care
Affinity Asset Advisors, LLC reported holding 1,279,134 shares of SYRE (SPYRE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$113.9M, representing 5.30% of its reported portfolio and ranking #3 among its reported holdings. Affinity Asset Advisors, LLC has disclosed SYRE holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Affinity Asset Advisors, LLC's SYRE position evolved
Affinity Asset Advisors, LLC first disclosed a stake in SYRE in Q3 2023 at 242,297 shares (US$3.0M). The position peaked in Q3 2026 at 1,279,134 shares, worth US$113.9M. Across 13 filings, Affinity Asset Advisors, LLC increased the stake 6 time(s), trimmed it 4 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 1,279,134 shares valued at US$113.9M. Notable position changes include a 114% increase in Q4 2023 (shares rose 9% over the following quarter), a 65% increase in Q4 2024 (shares fell 31% over the following quarter), a 134% increase in Q3 2025 (shares rose 95% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 242.30K | $2.97M | New |
| Q4 2023 | 517.55K | $11.14M | Add |
| Q1 2024 | 410.00K | $15.55M | Reduce |
| Q2 2024 | 513.42K | $12.07M | Add |
| Q3 2024 | 498.42K | $14.66M | Reduce |
| Q4 2024 | 824.33K | $19.19M | Add |
| Q1 2025 | 481.68K | $7.77M | Reduce |
| Q2 2025 | 606.68K | $9.08M | Add |
| Q3 2025 | 1.42M | $23.79M | Add |
| Q4 2025 | 1.43M | $46.93M | Add |
| Q1 2026 | 1.28M | $64.52M | Reduce |
| Q2 2026 | 1.28M | $113.56M | Hold |
| Q3 2026 | 1.28M | $113.88M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SYRE and 13F data
SYRE (SPYRE THERAPEUTICS INC) is a Health Care company. 65 other funds we track also report a position in SYRE — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$383.5M), RTW INVESTMENTS, LP (US$377.5M), Paradigm Biocapital Advisors LP (US$341.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SYRE
- PERCEPTIVE ADVISORS LLC 4.32M sh · $383.48M · Q2 2026
- RTW INVESTMENTS, LP 4.25M sh · $377.49M · Q2 2026
- Paradigm Biocapital Advisors LP 3.84M sh · $340.98M · Q2 2026
- Venrock Adviser, LLC 2.99M sh · $265.05M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 2.80M sh · $248.51M · Q2 2026
- TCG Crossover Management, LLC 1.90M sh · $168.73M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 1.89M sh · $167.99M · Q2 2026
- Remedium Capital Partners, LLC 1.16M sh · $103.33M · Q3 2026
- BRAIDWELL LP 879.47K sh · $78.08M · Q2 2026
- Siren, L.L.C. 868.60K sh · $77.33M · Q3 2026
- Commodore Capital LP 846.79K sh · $75.18M · Q2 2026
- EMERALD ADVISERS, LLC 571.05K sh · $50.84M · Q3 2026
More on Affinity Asset Advisors, LLC
FAQ
How long has Affinity Asset Advisors, LLC held SYRE?
Affinity Asset Advisors, LLC has disclosed SYRE holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Affinity Asset Advisors, LLC's current position in SYRE?
As of Q3 2026, Affinity Asset Advisors, LLC holds 1.28M shares of SYRE (SPYRE THERAPEUTICS INC), valued at $113.88M, representing 5.30% of its reported portfolio and ranking #3.
Has Affinity Asset Advisors, LLC been buying or selling SYRE?
In the latest 13F filing (Q3 2026), Affinity Asset Advisors, LLC held unchanged its position in SYRE. The position peaked in Q3 2026 at 1.28M shares.
Which other funds hold SYRE?
Other major institutional holders of SYRE include PERCEPTIVE ADVISORS LLC, RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, among 65 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.